The first China Pharmaceutical Innovation and Investment Conference

Source: China Council for the promotion of drugs 2016-12-29 recently, an article entitled "promoting biomedical innovation in China" was published in nature (22 / 29 December 2016 / vol 540 / issue no 7634), which was jointly sponsored by China Council for the promotion of pharmaceutical innovation and China Securities Association“ China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as Venture Capital Conference) made a detailed report Through the three parts of "policy reform", "investment environment" and "progress of innovative drugs", the report comprehensively introduces the current situation of China's pharmaceutical innovation and development, the improvement of pharmaceutical regulatory policies and the thinking on the existing problems of China's pharmaceutical innovation and investment presented at the venture capital conference Song Ruilin, executive director of China pharmaceutical innovation promotion association, pointed out that "since the implementation of major national new drug projects in 2008, 24 national first-class new drugs have been approved But we still have a long way to go The organic combination of innovative R & D and capital market is the key to success " Sun Xianze, deputy director of the State Food and Drug Administration (CFDA), said that "China is carrying out a series of reforms, such as accelerating drug review, redefining the concept of new drugs, and evaluating the quality consistency of generic drugs, in order to promote innovative research and development of biomedicine." Zhou Siyuan, deputy director of CFDA national drug review center, said that "by simplifying the review process, CFDA currently processes more than 1000 drug declarations per month on average, effectively solving the drug backlog." Tian Yuan, founding partner of Yuanming capital, pointed out that "China's pharmaceutical industry needs to establish a quotation evaluation system based on in-depth understanding of biomedical specialty to effectively guide investors." Philip Ross, managing director of JPMorgan healthcare investment banking, said: "the biomedical sector has performed well in the capital markets Emerging economies, especially China's pharmaceutical market, contribute a lot to global economic growth " Academician Chen Kaixian, deputy chief engineer of major new drug technology and chairman of Shanghai Association of science and technology, pointed out that the gap between China's top pharmaceutical enterprises and international pharmaceutical enterprises is narrowing, "with the continuous improvement of policy environment, China's new drug research and development is expected to make a significant leap in the next five years." Wang Xiang, member of the Standing Committee of Suzhou Municipal Committee, deputy mayor and Secretary of Suzhou Industrial Park Working Committee, said that "new drug research and development has an important contribution to promoting people's health and social and economic development Suzhou Industrial Park is pleased to be the permanent site of the venture capital conference " The report praised the first launch of clinical research data of innovative drugs as the highlight of the venture capital conference, and the results of clinical research and development of Chinese original drugs displayed by enterprises were exciting In particular, the breakthrough new antitumor drug chlorogenic acid for injection, which was originally used in the treatment of gliomas in Sichuan, was reported in detail Studies have shown that chlorogenic acid can penetrate the blood-brain barrier and induce tumor cell differentiation, thus transforming tumor cells into healthy cells Nature reports the Venture Capital Conference in detail in two pages, which is not only a full recognition of the efforts and influence of the venture capital conference to promote the integration of Chinese pharmaceutical innovation and investment, but also an affirmation and expectation for the opening of the original mode and good future prospects of Chinese innovative drug research and development